A Chirca1, E Radu2, D G Minca3, R Costea4. 1. PhD student, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 2. Histology and Cell Biology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 3. Department of Public Health, "Carol Davila" University of Medicine and Pharmacy, Institute of National Health, Bucharest, Romania. 4. 2nd Department of Surgery, University Emergency Hospital, Bucharest, Romania.
Abstract
OBJECTIVES: Colorectal cancer (CRC) is the third most common type of cancer, the fourth leading cause of cancer related deaths worldwide and a major public health issue. Management is difficult, especially in elderly patients, and efforts for an individualized treatment are an asset for patients' wellbeing. Factors such as cumulated comorbidities, disease stage, and operative time may increase the length of hospitalization (LOH) and overall costs. The aim of this paper is to assess the impact of a single nucleotide polymorphism (SNP) - rs6983267 - on CRC risk in Romanian individuals. MATERIALS AND METHODS: A case-control genotyping molecular study was performed on 32 patients diagnosed with CRC (median age 67.5 years) who underwent elective surgery and 30 patients withour CRC (median age 66 years). Genotyping rs6983267 was performed on DNA extracted from peripheral venous blood. RESULTS: Twenty fice patients were diagnosed with colonic cancer with different localizations, whereas seven had rectal cancers. Median LOH was 16.5 days. Genotyping for rs6983267 revealed no heterozygous (G/T) individuals within the control group, with all patients showing homozygous profiles (76.67% G/G, and 23.33% T/T), but the heterozyhous (G/T) genotype was present in 59.38% of the patients in the study group (with 21.88% G/G and 18.75% T/T genotypes). CONCLUSION: A higher percentage of CRC patients had at least one G allele (81.21%) when compared to controls (76.57%), although G allele frequency was higher in the control group due to an increased percentage of G/G homozygosity. When comparing clinical data between groups, we found an association between the lenght of hospitalization and factors that influenced operating time. Further research is still necessary to accurately calculate a CRC risk associated with the presence of this SNP in a Romanian population.
OBJECTIVES: Colorectal cancer (CRC) is the third most common type of cancer, the fourth leading cause of cancer related deaths worldwide and a major public health issue. Management is difficult, especially in elderly patients, and efforts for an individualized treatment are an asset for patients' wellbeing. Factors such as cumulated comorbidities, disease stage, and operative time may increase the length of hospitalization (LOH) and overall costs. The aim of this paper is to assess the impact of a single nucleotide polymorphism (SNP) - rs6983267 - on CRC risk in Romanian individuals. MATERIALS AND METHODS: A case-control genotyping molecular study was performed on 32 patients diagnosed with CRC (median age 67.5 years) who underwent elective surgery and 30 patients withour CRC (median age 66 years). Genotyping rs6983267 was performed on DNA extracted from peripheral venous blood. RESULTS: Twenty fice patients were diagnosed with colonic cancer with different localizations, whereas seven had rectal cancers. Median LOH was 16.5 days. Genotyping for rs6983267 revealed no heterozygous (G/T) individuals within the control group, with all patients showing homozygous profiles (76.67% G/G, and 23.33% T/T), but the heterozyhous (G/T) genotype was present in 59.38% of the patients in the study group (with 21.88% G/G and 18.75% T/T genotypes). CONCLUSION: A higher percentage of CRC patients had at least one G allele (81.21%) when compared to controls (76.57%), although G allele frequency was higher in the control group due to an increased percentage of G/G homozygosity. When comparing clinical data between groups, we found an association between the lenght of hospitalization and factors that influenced operating time. Further research is still necessary to accurately calculate a CRC risk associated with the presence of this SNP in a Romanian population.
Authors: Christopher A Haiman; Nick Patterson; Matthew L Freedman; Simon R Myers; Malcolm C Pike; Alicja Waliszewska; Julie Neubauer; Arti Tandon; Christine Schirmer; Gavin J McDonald; Steven C Greenway; Daniel O Stram; Loic Le Marchand; Laurence N Kolonel; Melissa Frasco; David Wong; Loreall C Pooler; Kristin Ardlie; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Esther M John; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich Journal: Nat Genet Date: 2007-04-01 Impact factor: 38.330
Authors: H S Snijders; M W J M Wouters; N J van Leersum; N E Kolfschoten; D Henneman; A C de Vries; R A E M Tollenaar; B A Bonsing Journal: Eur J Surg Oncol Date: 2012-09-03 Impact factor: 4.424
Authors: Aalok Kumar; Hagen F Kennecke; Daniel J Renouf; Howard J Lim; Sharlene Gill; Ryan Woods; Caroline Speers; Winson Y Cheung Journal: Cancer Date: 2014-10-20 Impact factor: 6.860
Authors: Ernst J Kuipers; William M Grady; David Lieberman; Thomas Seufferlein; Joseph J Sung; Petra G Boelens; Cornelis J H van de Velde; Toshiaki Watanabe Journal: Nat Rev Dis Primers Date: 2015-11-05 Impact factor: 52.329
Authors: Clemens Schafmayer; Stephan Buch; Henry Völzke; Witigo von Schönfels; Jan Hendrik Egberts; Bodo Schniewind; Mario Brosch; Andreas Ruether; Andre Franke; Micaela Mathiak; Bence Sipos; Tobias Henopp; Jasmin Catalcali; Stephan Hellmig; Abdou ElSharawy; Alexander Katalinic; Markus M Lerch; Ulrich John; Ulrich R Fölsch; Fred Fändrich; Holger Kalthoff; Stefan Schreiber; Michael Krawczak; Jürgen Tepel; Jochen Hampe Journal: Int J Cancer Date: 2009-01-01 Impact factor: 7.396